Online first
Original article
Published online: 2024-08-08
The effect of glucagon-like peptide 1 receptor agonists on alcohol and tobacco craving among patients with type 2 diabetes mellitus: a cross-sectional, questionnaire pilot study
1
, 2, 3, 4, 2
, 2, 3, 4, 2
Abstract
Introduction: Glucagon-like peptide 1 receptor (GLP-1R) agonists are widely used in therapy for type 2 diabetes mellitus (DM2) and obesity. There are also increasing amounts of data concerning the effectiveness of these drugs in the treatment of addictive disorders. This pilot study aimed to assess changes in alcohol-drinking and cigarette-smoking behaviours after the introduction of GLP-1R agonist therapy in patients with DM2.
Methods: Forty-eight (48) patients with obesity and DM2 being treated with GLP-1R agonists completed a questionnaire designed by researchers, the Penn Alcohol Craving Scale (PACS), the Fagerstrom Test for Nicotine Dependence, and the Hunger-Satiety Scale. The severity of alcohol craving and nicotine dependence was compared between one month prior and the week before the evaluation.
Results: Among the 48 patients enrolled on the study, 25 (52%) were treated with liraglutide, 11 (23%) with semaglutide and 12 (25%) with dulaglutide. It was found that changes in PACS total score were statistically significant only in patients treated with semaglutide and that these changes were affected by BMI, marital status, and whether the patient stated that they drank alcohol or smoked cigarettes. Smokers treated with semaglutide had lower Fagerstrom total scores than patients treated with liraglutide.
Conclusion: Semaglutide exerts a reducing effect on alcohol and nicotine craving that was not seen for liraglutide or dulaglutide.
Keywords: GLP-1 receptor agonistalcohol cravingnicotine cravingquestionnaire
References
- Cimino G, Vaduganathan M, Lombardi CM, et al. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail. 2024; 11(2): 649–661.
- Raven LM. Understanding the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists. Trends Cardiovasc Med. 2024 [Epub ahead of print].
- Hong SH, Choi KM. Gut hormones and appetite regulation. Curr Opin Endocrinol Diabetes Obes. 2024; 31(3): 115–121.
- Lewis JoE, Nuzzaci D, James-Okoro PP, et al. Stimulating intestinal GIP release reduces food intake and body weight in mice. Mol Metab. 2024; 84: 101945.
- Barakat GM, Ramadan W, Assi G, et al. Satiety: a gut-brain-relationship. J Physiol Sci. 2024; 74(1): 11.
- Kitamura T. Glucagon: Physiological and Pharmacological Functions and Pathophysiological Significance in Type 2 Diabetes. Endocrinol Metab (Seoul). 2024; 39(1): 33–39.
- Camilleri M. The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions. Neurogastroenterol Motil. 2024; 36(2): e14660.
- Ziółkowski M, Czarnecki D, Budzyński J, et al. Orexin in Patients with Alcohol Dependence Treated for Relapse Prevention: A Pilot Study. Alcohol Alcohol. 2016; 51(4): 416–421.
- Alhabeeb H, AlFaiz A, Kutbi E, et al. Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids. Nutrients. 2021; 13(2).
- Czarnecki D, Ziółkowski M, Chodkiewicz J, et al. Confusion of Alcohol Craving With Food Hunger in Alcohol-Dependent Individuals Entering In-Patient Drug Treatment. Alcohol Alcohol. 2023; 58(2): 151–158.
- Dumiaty Y, Underwood BM, Phy-Lim J, et al. Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY in the suppression of food, drug-seeking, and anxiogenesis. Neuropeptides. 2024; 105: 102427.
- Jerlhag E. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Brain Res. 2020; 1727: 146562.
- Klausen MK, Thomsen M, Wortwein G, et al. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022; 179(4): 625–641.
- Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023; 14: 1063033.
- Douton JE, Acharya NK, Stoltzfus B, et al. Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats. Behav Pharmacol. 2022; 33(5): 364–378.
- Shevchouk OT, Tufvesson-Alm M, Jerlhag E. An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side. Front Neurosci. 2021; 15: 774050.
- Yammine L, Green CE, Kosten TR, et al. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021; 23(10): 1682–1690.
- Tufvesson-Alm M, Shevchouk OT, Jerlhag E. Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin. Front Psychiatry. 2022; 13: 1092828.
- Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023; 13(1): 20998.
- Lengsfeld S, Burkard T, Meienberg A, et al. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2023; 57: 101865.
- Herman RJ, Hayes MR, Audrain-McGovern J, et al. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology (Berl). 2023; 240(6): 1373–1386.
- Zhang Z, Zhang Q, Tan Y, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol (Lausanne). 2023; 14: 1149328.
- Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013; 8(10): e77284.
- Lüthi H, Lengsfeld S, Burkard T, et al. Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2024; 68: 102429.
- Lempesis IG, Liu J, Dalamaga M. The : Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metabol Open. 2022; 16: 100220.
- The Hunger-Satiety Scale. https://uhs.berkeley.edu/sites/default/files/wellness-hungersatietyscale.pdf.
- Chodkiewicz J, Ziółkowski M, Czarnecki D, et al. Validation of the Polish version of the Penn Alcohol Craving Scale (PACS). Psychiatr Pol. 2018; 52(2): 399–410.
- Fagerstrom Test for Nicotine Dependence (FND). https://cde.nida.nih.gov/sites/nida_cde/files/FagerstromTest_2014Mar24.pdf.
- Weinland C, Mühle C, Kornhuber J, et al. Body mass index and craving predict 24-month hospital readmissions of alcohol-dependent in-patients following withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 90: 300–307.
- Clay JM, Adams C, Archer P, et al. Psychosocial stress increases craving for alcohol in social drinkers: Effects of risk-taking. Drug Alcohol Depend. 2018; 185: 192–197.
- Eren-Yazicioglu CY, Yigit A, Dogruoz RE, et al. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2020; 14: 614884.
- Bremmer MP, Hendershot CS. Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders. J Stud Alcohol Drugs. 2024; 85(1): 5–11.
- Smith CL, Jenkins G, Burduli E, et al. Crossover associations of alcohol and smoking, craving and biochemically verified alcohol and nicotine use in heavy drinking smokers. Behav Pharmacol. 2020; 31(7): 702–705.
- Motschman CA, Tiffany ST. Combined smoking and alcohol cues: Effects on craving, drug-seeking, and consumption. Alcohol Clin Exp Res. 2021; 45(9): 1864–1876.
- Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024; 15(1): 4548.